REG - Zotefoams PLC - Chair Succession

ZotefoamsAnnouncement

17/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230117:nRSQ8885Ma&default-theme=true

RNS Number : 8885M  Zotefoams PLC  17 January 2023

Zotefoams plc

(the 'Company' or 'Group')

 

Chair Succession

 

17 January 2023 - Zotefoams (LSE: ZTF), a world leader in cellular materials
technology, today announces details of changes to its Board of Directors (the
'Board').

 

In line with the provisions of the UK Corporate Governance Code, the term of
office of the existing Chair of the Company, Steve Good, is due to end in
2023. Following an assessment of the Board's existing skillsets against those
required to deliver the Company's strategy, a search process led by the Senior
Independent Director and supported by Korn Ferry was initiated in mid-2022 to
identify and appoint a new Chair.

 

The search has been successfully concluded and we are pleased to announce the
appointment of Dr Lynn Drummond as an Independent Non-Executive Director and
Chair Designate.

 

Lynn is currently Chair and Pro-Chancellor of the University of Hertfordshire
and a Board mentor for Criticaleye. Previously, she was a Non-Executive
Director with Venture Life Group plc, RPC Group plc, Infirst Healthcare,
Shield Holdings AG, Allocate Software plc, Consort Medical plc and Alimentary
Health Ireland. Lynn spent 16 years as a Managing Director within Investment
Banking for Rothschild. Prior to Rothschild, Lynn worked in the Cabinet Office
in London as Private Secretary to the Chief Scientific Advisor. She has also
been Chairman of Trustees for Breast Cancer Haven and was on the University of
Cambridge, Centre for Science and Policy Development Group. Lynn holds a
Bachelor of Science Degree in Chemistry from the University of Glasgow and a
PhD in Biochemistry from the University of London. She is a Fellow of the
Royal Society of Chemistry and a Fellow of the Royal Society of Edinburgh.

 

Lynn will take over as Chair following Zotefoams' Annual General Meeting on 24
May 2023, at which point Steve will retire from the Board.

 

Douglas Robertson, Senior Independent Director, said: "On behalf of the Board,
I would like to thank Steve for his significant contribution to the Zotefoams
Group and, in particular, his leadership as Chair. We wish him the best in his
future endeavours."

 

David Stirling, Group CEO, said: "I am delighted to welcome Lynn to Zotefoams.
Lynn brings considerable knowledge across a number of functions and sectors,
including a long and distinguished career in life sciences. She brings
extensive and relevant quoted-company experience and expertise to the Group. I
look forward to working with her as we focus on delivering the next phase of
our growth strategy."

 

Lynn Drummond said: "Zotefoams is a pioneer in cellular materials with the
purpose of creating optimal material solutions for the benefit of society. I
look forward to working with the Board as we focus on delivering long-term,
sustainable growth in the interests of all our stakeholders."

 

There is no further information which would require disclosure under LR9.6.13
of the Listing Rules of the Financial Conduct Authority.

 

Enquiries:

 

 Zotefoams plc                +44 (0) 208 664 1600
 David Stirling, Group CEO
 Gary McGrath, Group CFO

 IFC Advisory                 +44 (0) 203 934 6630
 Graham Herring

 Tim Metcalfe

 Zach Cohen

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology
delivering optimal material solutions for the benefit of society. Utilising a
variety of unique manufacturing processes, including environmentally friendly
nitrogen expansion for lightweight AZOTE(®) polyolefin and ZOTEK(®)
high-performance foams, Zotefoams sells to diverse markets worldwide.
Zotefoams uses its own cellular materials to manufacture T-FIT(®) advanced
insulation for demanding industrial markets. Zotefoams also owns and licenses
patented microcellular foam technology to reduce plastic use in extrusion
applications and for ReZorce(®) mono-material recyclable barrier packaging.

 

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites
in Kentucky, USA, Brzeg, Poland (foam manufacture), Oklahoma, USA (foam
products manufacture and conversion), Massachusetts, USA, Stilling, Denmark
(microcellular foam technology) and Jiangsu Province, China (T-FIT).

 

www.zotefoams.com (http://www.zotefoams.com)

 

AZOTE(®), ZOTEK(®), ReZorce(®) and T-FIT(®) are registered trademarks of
Zotefoams plc.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEAXFKFEPDEFA